Basilea Pharmaceutica AG
SIX:BSLN.SW
43.65 (CHF) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Basilea Pharmaceutica AG |
Symbool | BSLN.SW |
Munteenheid | CHF |
Prijs | 43.65 |
Beurswaarde | 529,088,896 |
Dividendpercentage | 0% |
52-weken bereik | 32 - 47.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. David Veitch |
Website | https://www.basilea.com |
An error occurred while fetching data.
Over Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CHF)
Cijfers zijn in miljoenen (CHF)